107 results
Page 5 of 6
8-K
EX-99.1
d7r9 0xfz
16 Mar 20
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
9:01am
8-K
EX-99.1
vm2degt
12 Nov 19
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
4:02pm
424B5
nbqyb6gzzaplj
7 Nov 19
Prospectus supplement for primary offering
4:05pm
424B5
rjgiks0o
6 Nov 19
Prospectus supplement for primary offering
5:31pm
8-K
EX-99.1
3qjk696 ye
4 Nov 19
Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update
5:10pm
8-K
EX-99.2
mzwzqwk
23 Oct 19
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTACĀ® Targeted Protein Degraders
6:39am
8-K
EX-99.1
ut6houwm yh
23 Oct 19
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTACĀ® Targeted Protein Degraders
6:39am
424B3
wbnh9egg21pdnwnf5vj
18 Oct 19
Prospectus supplement
5:05pm
424B3
4k6ue405m q3mggc
11 Oct 19
Prospectus supplement
7:44am
S-3
kdvt6bhfk2f7k67wxc7
1 Oct 19
Shelf registration
6:37pm
8-K
EX-99.1
w3wohzje t4
5 Aug 19
Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update
4:05pm
8-K
08omjp alioxzk3
16 Jul 19
Entry into a Material Definitive Agreement
4:49pm
8-K
2wz661 rof
4 Jun 19
Entry into a Material Definitive Agreement
7:18am
8-K
EX-99.1
cdie1r
8 May 19
Arvinas Reports First Quarter Financial Results and Provides Corporate Update
5:27pm